Ahead of the April 2 rollout of its reciprocal tariff plan, the United States Trade Representative (USTR) has raised concerns ...

A multicenter study led by Cedars-Sinai created a database of adverse medication events—the fourth leading cause of death in ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) ...

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...

Scientists at the University of Lausanne (UNIL) and University center Unisanté classified 35 commonly used drugs in Switzerland based on their impact on the aquatic biodiversity. The aim of this ...

Novartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the ...

The therapy is the fourth clinical-stage programme derived from the company’s chemoproteomics discovery platform.

Experts discuss how cancer treatment and survivorship can be made more equitable and affordable through advocacy, outreach, and effective communication tools. Beyond Cancer: Caring for Young ...

Today, the National Quantum Computing Centre (NQCC) launched its first Insights Paper, "The convergence of healthcare and pharmaceuticals with quantum computing: A new fronter in medicine ...

A low-density lipoprotein cholesterol (LDL-C) level below 70 mg/dL was associated with a 26% reduced risk of all-cause dementia and a 28% lower risk of Alzheimer’s disease-related dementia (ADRD ...